Last reviewed · How we verify
NCT00686933
The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Study M10-346
Phase 2 trial testing ABT-089 in Attention-Deficit/Hyperactivity Disorder in 117 participants. Completed in 1 October 2008.
1 October 2008
Quick facts
| Lead sponsor | AbbVie (prior sponsor, Abbott) |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 117 |
| Start date | 1 May 2008 |
| Primary completion | 1 October 2008 |
| Estimated completion | 1 October 2008 |
| Sites | 12 locations across United States |
Drugs / interventions tested
- ABT-089 — full drug profile →
Conditions studied
- Attention-Deficit/Hyperactivity Disorder — all drugs for Attention-Deficit/Hyperactivity Disorder →
Sponsor
AbbVie (prior sponsor, Abbott) — full company profile →
Who can join
Adults 18 to 60, any sex, with Attention-Deficit/Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
CAARS:Inv
Time frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 -
CGI-ADHD-S
Time frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24
Sponsor's own description
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00686933
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Attention-Deficit/Hyperactivity Disorder
Currently open trials in the same condition.
- NCT07327775 — Fibromyalgia Disease Burden in Mothers of Children With Attention-Deficit/Hyperactivity Disorder · recruiting
Other AbbVie (prior sponsor, Abbott) trials
Trials by the same sponsor.
- NCT01609933 — A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterfer · Phase 2 · completed
- NCT01657799 — Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases · Phase 2 · completed
- NCT01736189 — Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice · completed
- NCT01620528 — A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Assoc · Phase 3 · completed
- NCT01506947 — A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calc · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00686933 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AbbVie (prior sponsor, Abbott)
- Last refreshed: 11 January 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00686933.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing